DocWire News Editors

DocwireNews

The introduction of any new treatment regimen requires a period of adjustment for the clinicians charged with using it. Teprotumumab was approved by the FDA in January for the treatment of thyroid eye disease (TED). Three experts recently discussed use of the drug in TED during an Ask the Experts session at the American Academy of Ophthalmology 2020 Virtual meeting.&ldquo;There has been a paradigm shift in TED, and clinicians are now able to offer patients new options,&rdquo; said Sara T. Wester, MD, FACS, of University of Miami Health System.During the session, Dr. Wester, together with Andrea N. Kossler, MD, of Stanford University School of Medicine, and Andrea A. Tooley, MD, of Mayo Clinic, answered questions from the virtual audience about updates in TED.The first question they discussed was, &ldquo;Tell us more about how to use teprotumumab?&rdquo;&ldquo;Teprotumumab has totally changed my practice,&rdquo; said Dr. Kossler, adding that she now uses the drug as her first-line treatment for patients with active moderate to severe TED. &ldquo;Clinical trials tell us that this drug leads to significant improvement in proptosis, double vision, Clinical Activity Scores (CAS), and quality of life,&rdquo; she said.There are also some patients who would previously be considered as having stable disease that she has seen improvement in with teprotumumab. Dr. Wester agreed, adding that she has also used the drug in patients with smoldering or more chronic disease and had great results. &ldquo;I&rsquo;m definitely looking forward to ongoing studies in chronic patients,&rdquo; Dr. Wester said. &ldquo;We have a lot to learn about who might benefit the most from this drug.&rdquo;The second question discussed was about what side effects occur with teprotumumab and how best to handle them. &ldquo;There is a paper coming out soon in the Journal of Neuro-Ophthalmology that is an attempt at a guideline on this from some investigators involved in the phase III OPTIC study,&rdquo; Dr. Wester said.In her own practice, she said that if a patient has an underlying issue with true diabetes or impaired glucose tolerance, she will follow the patient more closely. For patients with normal HbA1c and glucose, she checks glucose at baseline, week 12, and week 24. She also gets a complete blood count and CHEM-7 panel. In addition, she also gets a urine analysis for women of child-bearing age. Finally, she always asks patients if they have a history of inflammatory bowel disease.In clinical trials, muscle cramps were the most common side effect. Thinning of the hair may also occur. &ldquo;I find though that I have to really have to ask about these specific things,&rdquo; Dr. Kossler said.In fact, both she and Dr. Wester said that they have experienced patients not wanting to admit experiencing side effects because they are so satisfied with the drug and do not want to have to stop taking it.The final question from the audience was about the cost of teprotumumab and how best to get insurance approval for its use.Teprotumumab is an expensive treatment, and clinicians may run into some issues getting insurance to cover treatment, Dr. Westner said. However, both Drs. Westner and Kossler said they have protocols in place on what information must be included in the chart to gain approval.&ldquo;We include the CAS, amount of proptosis, other treatments that we have done or failed, why a patient can&rsquo;t have steroids or why steroids are not a good idea, why the patient is not a good candidate for radiation, and a complete examination,&rdquo; Dr. Kossler said. &ldquo;I think if you send a complete note with justification, you have a better chance of getting approved.&rdquo;

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Jordana Jampel

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Latest News

Ask the Experts: Use of Teprotumumab in Thyroid Eye Disease

AAO 2020

The introduction of any new treatment regimen requires a period of adjustment for the clinicians charged with using it. Teprotumumab was approved by the FDA in January for the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe